Bayer highlights hemophilia strategy as newer drugs carry pharma unit in 2Q
This article was originally published in Scrip
Executive Summary
Bayer's pharmaceutical unit produced better than expected sales for the second quarter of the year, and the business is on track to meet its above €4bn sales target for five of its leading brands by the year's end.